Abstract

The prostaglandin PGE<sub>2</sub>, a metabolite of the cyclooxygenase pathway, activates Ca<sup>2+</sup>-permeable cation channels in erythrocyte cell membranes leading to entry of Ca<sup>2+</sup> with subsequent eryptosis, i.e. cell shrinkage, breakdown of phosphatidylserine (PS) asymmetry and membrane blebbing, all features typical for apoptosis in nucleated cells. PS exposing cells are recognized by macrophages, engulfed, degraded and thus cleared from circulating blood. The present study explored whether the specific lipoxygenase inhibitor Bay-Y5884 influences eryptosis. As determined by competitive ELISA, Bay-Y5884 (20 µM) enhanced the release of PGE<sub>2</sub> from human erythrocytes. According to whole-cell patch-clamp, Bay-Y5884 (20 µM) activated nonselective cation channels. The effect of Bay-Y5884 on cation channels was abolished by the cyclooxygenase inhibitor diclophenac (10 µM). Bay-Y5884 (30-40 µM) significantly increased erythrocyte free Ca<sup>2+</sup> concentration and PS exposure as analyzed in flow cytometry by Fluo3 fluorescence and annexin-V binding, respectively. PS exposure triggered by 20 µM (but not by 40 µM) Bay-Y5884 was blunted by cyclooxygenase inhibitors acetylsalicylic acid (50 µM) and diclophenac (10 µM). In conclusion, the lipoxygenase inhibitor Bay-Y5884 enhances erythrocyte PGE<sub>2</sub> formation with subsequent activation of non-selective cation channels, Ca<sup>2+</sup> entry and phospholipid scrambling.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.